Perioperative clopidogrel is seven days enough?

Area of Science:

• Cardiology
• Surgical Oncology
• Pharmacology

Background:

• Clopidogrel is frequently used by surgical candidates.
• Current guidelines for preoperative clopidogrel cessation are lacking.
• A 7-day clopidogrel withdrawal period is often considered standard practice.

Purpose of the Study:

• To evaluate the safety of the 7-day clopidogrel cessation period.
• To assess the incidence of major bleeding events, including reoperation and blood transfusions, in patients taking clopidogrel perioperatively.

Main Methods:

• Retrospective analysis of 170 patients on clopidogrel during the perioperative period (2005-2007).
• Comparison with 34,480 non-clopidogrel patients undergoing surgery at the same institution.
• Analysis of reoperation rates for bleeding and blood transfusion requirements.

Main Results:

• Patients on clopidogrel had a significantly higher rate of reoperation for bleeding (6.5%) versus non-clopidogrel patients (0.015%).
• No significant difference in reoperation rates was observed between patients stopping clopidogrel >7 days preoperatively (5%) and those not stopping (7.5%).
• Blood transfusion rates did not significantly differ between the clopidogrel subgroups.

Conclusions:

• Perioperative clopidogrel use is associated with a substantially increased risk of reoperation for bleeding.
• A 7-day preoperative clopidogrel cessation is insufficient to mitigate this elevated risk.
• Further research is needed to establish optimal antiplatelet management strategies for surgical patients.